Posted by Michael Wonder on 02 Dec 2021
Pfizer Canada initiates submission to Health Canada for COVID-19 oral anti-viral candidate
1 December 2021 - Pfizer Canada today initiated the filing of a rolling new drug submission with Health Canada for its investigational oral anti-viral candidate PF-07321332; ritonavir, for the treatment of mild to moderate COVID-19 in adults at increased risk of hospitalisations or death.
This submission includes clinical data from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in high risk Patients) interim analysis.
